

We Claim:

1. A pharmaceutical composition comprising a combination of:
 - a) Lactoferrin; and
 - b) one or more Guanosine Nucleotide or a pharmaceutically acceptable salt thereof.
- 5 2. The pharmaceutical composition as claimed in claim 1, wherein an amount of the Lactoferrin ranges from 5 to 90 % by wt. of the composition.
3. The pharmaceutical composition as claimed in claim 1, wherein the Guanosine Nucleotide
10 is selected from Guanosine monophosphate (GMP), Guanosine diphosphate (GDP), Guanosine triphosphate (GTP) or a combination thereof.
4. The pharmaceutical composition as claimed in claim 1, wherein a pharmaceutically acceptable salt of the Guanosine Nucleotide is selected from a hydrochloride, a sulfate, a
15 phosphate, acetate, lactate, citrate, a pantothenate, an ascorbate, a succinate, maleate, fumarate, gluconate, a magnesium salt, potassium, sodium, zinc, the salts of diethanolamine and a combination thereof.
5. The pharmaceutical composition as claimed in claim 1, wherein an amount of the
20 Guanosine Nucleotide ranges from 1 to 75% by wt. of the composition.
6. The pharmaceutical composition as claimed in claim 1, wherein the composition further comprises elemental iron, vitamin C, vitamin A, folic acid, folate, vitamin B or a combination thereof.
- 25 7. The pharmaceutical composition as claimed claim 6, wherein an amount of the elemental iron ranges from 30 to 45% by wt. of the composition.
8. The pharmaceutical composition as claimed claim 6, wherein an amount of the vitamin C
30 ranges from 5 to 65% by wt. of the composition.
9. The pharmaceutical composition as claimed in claim 6, wherein an amount of vitamin A ranges from 0.5 to 3% by wt. of the composition.

10. The pharmaceutical composition as claimed in claim 6, wherein an amount of folic acid or folate ranges from 0.05 to 0.75 % by wt. of the composition.
11. The pharmaceutical composition as claimed claim 6, wherein an amount of the vitamin B
5 ranges from 1 to 5% by wt. of the composition.
12. The pharmaceutical composition as claimed in claim 1, further comprising pharmaceutically acceptable excipients.
- 10 13. The pharmaceutical composition as claimed in claim 12, wherein the pharmaceutically acceptable excipients are selected from a diluent, a binder, a disintegrating agent, a lubricant, a glidant, coating agent, a solvent and combinations thereof.
14. The pharmaceutical composition as claimed in claim 13, wherein an amount of
15 the diluent ranges from 5% to 45% by wt. of the composition,
the binder ranges from 1% to 7% by wt. of the composition,
the disintegrating agent ranges from 1% to 25% by wt. of the composition,
the lubricant ranges from 0.5% to 5% by wt. of the composition,
the glidant ranges from 0.5% to 5% by wt. of the composition,
20 the coating agent ranges from 1% to 15% by wt. of the composition, or
the solvent is quantity sufficient.
15. The pharmaceutical composition as claimed in claim 1, wherein the composition is in the form of a tablet, capsule, pill, hard capsule filled with liquid or solid, soft capsule,
25 powder, granule, sachet, enteric coated tablet or capsule, modified release tablet or capsule.
16. A process for preparation of a composition as claimed in claim 1 comprising:
 (a) individually weighing all the ingredients in separate containers;
30 (b) sifting previously weighed Lactoferrin, Guanosine Nucleotide or a pharmaceutically acceptable salt thereof, and optionally adding elemental iron, vitamin C, vitamin A, folic acid, folate or vitamin B, diluent and disintegrating agent separately;
 (c) mixing contents of step (b);

- (d) optionally, preparing a binder solution in a separate container and adding contents to step (c), and sieving the formed granulated wet mass to obtain granules;
- (e) drying the obtained granulates until the level of dryness (LOD) is reduced to
5 between 3.0 to 5.0 % w/w;
- (f) sifting the semi-dried granules through a suitable sieve; and
- (g) sifting previously weighed lubricant(s) and glidant(s) separately through a suitable sieve and adding contents to step (f) to obtain the composition.
- 10 17. The pharmaceutical composition as claimed in claim 1, wherein the composition is used in treatment of Iron Deficiency Anaemia (IDA), Anaemia of Inflammation (AOI) and neuro-degenerative disorders.

15